secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001641489-25-000010
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on vTv Therapeutics' cadisegliatin Phase 3 diabetes trial
--------------------------------------------------------------------------------

- FDA lifted clinical hold effective March 14, 2025; CATT1 trial to resume after protocol amendment.
- Protocol amendment shortens trial from 12 to 6 months; primary endpoint (hypoglycemia rates) unchanged.
- Hold imposed July 26, 2024 due to chromatographic signal later found to be experimental artifact; no patients dosed.
- Cadisegliatin is a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes.
- Company expects shorter trial to expedite initiation of larger pivotal studies for NDA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000010/0001641489-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148925000010/vtvt-20250314.htm
  HTML page:      https://secwatch.observer/filing/0001641489-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer